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Pre-exposure prophylaxis (PrEP) is considered one of the five “pillars” by UNAIDS
to reduce HIV transmission. Moreover, it is a tool for female self-protection against
HIV, making it highly relevant to sub-Saharan regions, where women have the highest
infection burden. To date, Truvada is the only medication for PrEP. However, the cost
of Truvada limits its uptake in resource-constrained countries. Similarly, several currently
investigated, patent-protected compounds may be unaffordable in these regions. We set
out to explore the potential of the patent-expired antiviral efavirenz (EFV) as a cost-efficient
PrEP alternative. A population pharmacokinetic model utilizing data from the ENCORE1
study was developed. The model was refined for metabolic autoinduction. We then
explored EFV cellular uptake mechanisms, finding that it is largely determined by plasma
protein binding. Next, we predicted the prophylactic efficacy of various EFV dosing
schemes after exposure to HIV using a stochastic simulation framework. We predicted
that plasma concentrations of 11, 36, 1287 and 1486ng/mL prevent 90% sexual
transmissions with wild type and Y181C, K103N and G190S mutants, respectively.
Trough concentrations achieved after 600 mg once daily dosing (median: 2017 ng/mL,
95% CI:445–9830) and after reduced dose (400 mg) efavirenz (median: 1349ng/mL,
95% CI: 297–6553) provided complete protection against wild-type virus and the Y181C
mutant, and median trough concentrations provided about 90% protection against the
K103N and G190S mutants. As reduced dose EFV has a lower toxicity profile, we
predicted the reduction in HIV infection when 400 mg EFV-PrEP was poorly adhered
to, when it was taken “on demand” and as post-exposure prophylaxis (PEP). Once daily
EFV-PrEP provided 99% protection against wild-type virus, if≥50% of doses were taken.
PrEP “on demand” provided complete protection against wild-type virus and prevented
≥81% infections in the mutants. PEP could prevent >98% infection with susceptible
virus when initiated within 24 h after virus exposure and continued for at least 9 days.
We predict that 400 mg oral EFV may provide superior protection against wild-type HIV.
However, further studies are warranted to evaluate EFV as a cost-efficient alternative
to Truvada. Predicted prophylactic concentrations may guide release kinetics of EFV
long-acting formulations for clinical trial design.
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1. INTRODUCTION
The ambitious goals formulated by UNAIDS are to end
AIDS by 2030 (UNAIDS, 2017). However, unlike many other
infections, no cure is available to clear HIV infection. Ending
AIDS therefore heavily relies on strategies to reduce the
number of new HIV infections from an estimated 2.1 million
in 2014 (UNAIDS, 2015) to 500,000 cases by 2020 and
to fewer than 200,000 by 2030 (UNAIDS, 2016). While a
vaccine would be the ideal tool for the purpose, intrinsic
difficulties have so far precluded the development of an
effective vaccine against HIV. Despite these setbacks, the
development of about 30 antiviral compounds to stop HIV
replication has been an overwhelming success (Gulick, 2018) in
HIV research.
In light of the current situation, recent years have seen an
increasing interest in utilizing antivirals not only for treatment,
but also to prevent HIV transmission. Two general strategies are
currently investigated for this purpose:
(i) Treatment-as-prevention (TasP) intends to put individuals
with an HIV diagnosis immediately on treatment, which
essentially makes them non-contagious (Cohen et al., 2011).
However, a major limitation of this approach is that HIV is
typically transmitted early after infection (Brenner et al., 2007;
Yousef et al., 2016), when the recently infected individual is
unaware of his/her HIV status and has consequently not initiated
TasP. Thus, maximizing the epidemiological impact of TasP also
requires to improve HIV diagnosis, which is a central component
of the 90-90-90 strategy (UNAIDS, 2017).
(ii) Pre-exposure prophylaxis (PrEP) acts on the viral
dynamics in the virologically challenged individual immediately
after virus exposure. Akin to a vaccination, PrEP increases
the probability that transmitted virus gets cleared, protecting
individuals from becoming irreversibly infected. However,
unlike vaccination, PrEP protection is a direct function of the
concentration of prophylactic drugs at the target site.
Once-daily oral PrEP with the drug combination Truvada
(tenofovir disoproxil fumarate-emtricitabine) has been approved
since 2012 in the US and since 2016 in the EU. Initial clinical
studies with Truvada demonstrated its utility as a PrEP agent
(Grant et al., 2010), while subsequent studies indicated that
the efficacy of Truvada-based PrEP was highly dependent on
the individual’s adherence to the once daily regimen. While
it is difficult to quantify PrEP adherence clinically (Haberer
et al., 2015), efficacy estimates in apparently highly adherent
individuals were 86–100% in the IPrEx OLE study, 58–96%
in the PROUD study and 96% in the Partners PrEP OLE
study (Grant et al., 2014; McCormack et al., 2016). The
VOICE and FEM-PrEP studies indicated that Truvada may
not prevent infection in poorly adherent individuals, i.e., if
30% of individuals had detectable drug in their blood plasma
(Van Damme et al., 2012; Marrazzo et al., 2015). Mathematical
modeling of Truvada-based PrEP (Duwal et al., 2016) established
the precise relationship between drug pharmacokinetics and
prophylactic efficacy confirming many clinical observations (i.e.,
quantifying the prophylactic efficacy to be ≈ 96% in fully
adherent individuals).
While adherence is a major current concern that motivates
the identification of novel long-acting drug candidates and
optimized deployment strategies (AVAC, 2019), a currently
neglected factor is the cost of PrEP, with the majority of
HIV infections occurring in resource-constrained countries
(UNAIDS, 2016). Keller and Smith (2011) noted that the price of
Truvada currently undermines the advancement of pre-exposure
prophylaxis, particular in resource-constrained settings. Yet
regrettably, current PrEP research focusses entirely on patent-
protected compounds (AVAC, 2019). This makes it unlikely that
a current, or next-generation PrEP regimen will become broadly
implemented in resource-constrained regions where they could
benefit most. Moreover, PrEP is the only strategy by which
women can protect themselves against HIV infection, making
PrEP highly relevant in regions like sub-Saharan Africa, where
young women are the most relevant target group to halt the
ongoing spread of HIV (Dellar et al., 2015; Maxmen, 2016),
accounting for≈ 7000 infections per week (Mathur et al., 2016).
A natural progression would therefore be whether currently
neglected, patent-expired compounds might make good
candidates for PrEP repurposing. Based on an initial
computational assessment of potential candidates (Duwal
et al., 2019), we focus herein on the patent-expired non-
nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
(EFV), which is successfully used in HIV treatment, particularly
in resource-constrained settings, where it costs as little as 0.1US$
per day. To this end, we assess efavirenz pharmacokinetics,
consider its mode of action and establish the relationship
between pharmacokinetics and prophylactic efficacy. Since
reduced-dose (400 mg) efavirenz has a considerably improved
safety profile, we assess the prophylactic efficacy of 400 mg
oral EFV when used in chronic PrEP, PrEP on demand and
post-exposure prophylaxis (PEP).
2. PATIENTS
Apreviously developed population pharmacokinetic (PK)model,
constructed using data collected as part of ENCORE 1 was
used. ENCORE 1 was a multi-center, double-blind, placebo-
controlled trial designed to compare standard dose efavirenz
(600 mg once daily) to a reduced dose (400 mg once daily) in
HIV-infected, treatment-naive adults. Patients recruited at sites
across Africa, Asian, South America, Europe and Oceania were
randomized (1:1) to receive efavirenz 600 or 400 mg once daily
in combination with tenofovir disoproxil fumarate/emtricitabine
(Truvada, 300/200 mg once daily) (ENCORE1 Study Group,
2014; ENCORE1 Study Group et al., 2015).
At weeks 4 and 12 of therapy, single random blood samples
were drawn between 8-16 hours post-dose, additionally intensive
sampling was undertaken in a subgroup of patients between
weeks 4 and 8 [pre-dose (0 h), 2, 4, 8, 12, 16 and 24 h post-
dose]. Plasma efavirenz was quantified using a validated HPLC-
MS/MS method (Amara et al., 2011). Overall, 606 patients
(n=131, 32% female) randomized to efavirenz 600 mg (n = 311)
and 400 mg once daily (n = 295) contributed 1491 samples
for model development [median (range) 2 (1–9) per patient].
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Median (range) age and weight were 35 years (18–69) and
65kg (39–148) and baseline viral load ranged between 162
and 10,000,000 copies/mL. The majority of patients were of
African and Asian ethnicity (37 and 33%, respectively) with the
remainder identifying as Hispanic (17%), Caucasian (13%) and
Aboriginal and Torres Strait Islander (0.2%).
3. METHODS
3.1. Efavirenz Pharmacokinetics
Efavirenz (EFV) is a non-nucleoside reverse transcriptase
inhibitor that is frequently used in first-line therapy in resource-
constrained regions in combination with emtricitabine (FTC)
and tenofovir disoproxil fumerate (TDF) for treatment of
HIV infection. EFV is a small (molecular mass: 315.6 g/mol)
lipophilic (LogP ≈ 4) compound that is highly bound to plasma
proteins (human serum albumin and α-1-acid glycoprotein).
The unbound fraction of the drug in human plasma (fu) is
< 1% (Almond et al., 2005; Fayet et al., 2008; Burhenne
et al., 2010; Avery et al., 2011, 2013a). Efavirenz is a known
inducer of various CYP-P450 enzymes (Fichtenbaum and
Gerber, 2002), including CYP2B6, which is the main enzyme
mediating its own metabolism (Ward et al., 2003; Ogburn et al.,
2010). Moreover, it is known that CYP-P450 polymorphisms,
in particular CYP2B6 can lead to large inter-individual
variations in EFV concentrations (Orrell et al., 2016). We
derived statistical models for the inter-individual variability
in plasma pharmacokinetic profiles, particularly taking CYP
P450 polymorphisms (CYP2B6 and CYP2A6) in a representative
population (ENCORE 1) into account. Furthermore, we modeled
metabolic autoinduction and established the relationship
between plasma- and target-site concentrations.
3.1.1. Pharmacokinetic Model Building
The population pharmacokinetic analysis of ENCORE 1 has
previously been reported (Dickinson et al., 2015, 2016). Briefly,
nonlinear mixed effects modeling using NONMEM (v. 7.2; ICON
Development Solutions, Ellicott City, MD, USA) was applied to
the efavirenz concentration-time data using FOCE-I. The impact
of the following covariates on efavirenz apparent oral clearance
(CL/Fbio) was investigated: age, weight, fat-free mass (FFM),
body mass index (BMI), sex, ethnicity and CYP P450 genotypes
CYP2B6 516G>T, CYP2B6 983T>C, CYP2B6 15582C>T,
CYP2A6*9B, CYP2A6*17, CYP3A4*22, NR1I3 540C>T and
NR1I3 1089T>C. Specifically, of the 606 patients with PK data,
95% had a blood sample for genotyping (n=574), although
amplification failed for a small number of individuals (CYP2B6
15582C>T andCYP3A4*22, n=1;CYP2A6*17, n=2;CYP2A6*9B,
n=4). To drive the PrEP simulations, the final model was used
to simulate PK parameters of 1000 virtual patients receiving
efavirenz using the same distribution of significant covariates
as the original dataset. PK parameters of all virtual patients are
summarized in Supplementary Table 1.
Efavirenz concentrations over time were best described by a
1 compartment model parameterized by apparent oral clearance
[population value of CL/Fbio; estimate (RSE%): 11.9L/h (2.4%)
for the reference (wild-type) CYP genotype for all four SNPs;
CYP2B6: 516G>T/983T>C/CYP2A6*9B/*17 of a 70kg weighing
individual], apparent volume of distribution [population mean
V/Fbio; 282 L (5.2%)] and absorption rate constant ka fixed to a
value of 0.6h−1 (Arab-Alameddine et al., 2009):
d
dt
Z1 = −ka · Z1 (1)
d
dt
Di,j =
ka · Z1
Vi/Fbio
−
CLi,j(t)/Fbio
Vi/Fbio
· Di,j (2)
whereby Z1 denotes the amount of drug in the dosing
compartment. The variable of interest is the concentration in the
blood plasma (central compartment), i.e., D. Dosing events were
modeled as impulse inputs, with
Z1,t = Z1,t + dosek, (3)
whenever the current simulation time t coincided with a
dosing event τk. In the equations above, CLi,j(t)/Fbio denotes
the bioavailability-adjusted, individual drug clearance at
occasion j and ka denotes the rate of drug uptake. The
term Vi/Fbio is the bioavailability-adjusted volume of
distribution of individual i. Interindividual and interoccasion
variability was supported on CL/Fbio [36.6% (10.8%) and 21.0
(27.7%), respectively] and residual error was defined by a
proportional model [20% (8.6%)]. CL/Fbio and V/Fbio were
allometrically scaled by weight (centered on 70 kg) and CYP2B6
516G>T/983T>C/CYP2A6*9B/*17 composite genotype
significantly reduced efavirenz CL/Fbio between 4.5-82% ,
depending on allele combinations, compared to the reference
genotype. Pharmacokinetic parameters for a 70 kg individual
with reference genotype are summarized in Table 1. Overall,
there were 16 genotype subgroups (Supplementary Table 2).
Grouping of patients as extensive, intermediate or slow
metabolisers (see below) as part of the modelling process (or
after the final model was obtained) did not impact individual
parameter estimates. The reduced genotype groups were
defined as follows: (i) extensive metabolisers, (ii) intermediate
metabolisers and (iii) slow metabolisers as detailed in
Dickinson et al. (2015).
For initial model building clearance was assumed to reflect
values after metabolic autoinduction since pharmacokinetic data
was collected at weeks 4 and 12 of therapy. In the following, we
consider the autoinduction explicitly, since it affects PrEP efficacy
shortly after its initiation (e.g., “PrEP on demand”).
3.1.2. Metabolic Autoinduction
In our work, we modeled metabolic autoinduction similarly to
the model proposed by Zhu et al. (2009). We defined the term α
as the ratio of the mean clearance on day 1 to the mean clearance
at steady state (after autoinduction). The clearance ratio α is
then computed as α =
Ei(CLi,t0 )
Ei(CLi,SS)
where the average clearance
on the first day Ei(CLi,t0 ) = 5.76L/h was taken from Zhu et al.
(2009) and the average clearance at steady state E(CLi,SS) =
9.86L/h was computed from the virtual patient population
(Supplementary Table 1), deriving α = 0.58. For each virtual
patient generated from the population pharmacokinetic model,
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TABLE 1 | Pharmacokinetic parameters.
Parameter Value Unit Parameter Value Unit
CLss/Fbio 11.9 L/h V/Fbio 282 L
α 0.58 – σ 0.20 –
CVIIV (CLss/Fbio) 36.6 % CVIOV (CLss/Fbio) 21.0 %
The table displays the pharmacokinetic parameter estimates for a 70 kg individual with reference genotype (reference: CYP2B6, pos. 516:GG, pos. 516:TT and for CYP2A *9B and
*17: CC/CC or CC/CT or CC/TT or CA/CC or CA/CT or AA/CC or AA/CT Dickinson et al., 2015). Inter-individual variability (IIV), as well as inter-occasional variability (IOV) was included
on drug clearance CL/Fbio. These parameters were log-normal distributed with coefficient of variation [%] CV = 100 ·
√
eσ
2
− 1, where σ 2 is the variance of the associated normal
distribution. Weight was considered to affect CLss (i)/Fbio = CLss/Fbio · (weight(i)/70)
0.75 and the volume of distribution V (i)/Fbio = V/Fbio · (weight(i)/70) through allometric scaling.
Residual variability was described by a proportional error model (σ = 0.2).
the individual clearance at steady state was available and the
clearance at day 1 was computed using CLi,t0 = α · CLi,SS. Zhu
et al. (2009) proposed a model for time-dependent autoinduction
that we used herein
CLi(t) = CLi,t0 +
(
CLi,SS − CLi,t0
)
·
t − t0
(t − t0)+ T50
(4)
where CLi(t) is the individual clearance rate at the time t and t0
is the time of the first EFV dose. CLi(0) and CLi,SS represent the
clearance rates at day 1 and at steady state. The term T50 = 245h
(Zhu et al., 2009) is the time where the clearance rate reaches half
of its steady-state value.
3.1.3. Target-site Concentrations
The general perception is that only the free/unbound intracellular
concentration at the site of action (intracellular space) is
available to exert an antiviral effect (Smith et al., 2010). For
highly lipophilic drugs like EFV, passive diffusion may be
the dominating transport mechanisms and therefore the
unbound/free drug concentrations are identical on both sides
of biomembranes, whereas the relation between the total
concentrations can be computed by considering unspecific
drug retention by e.g. binding to plasma proteins or lipids.
These assumptions are implemented in so called partition
coefficient models commonly used in physiologically based
pharmacokinetic modeling, see von Kleist and Huisinga (2007)
for an overview. To test whether EFV is dominantly transported
into cells by passive diffusion/equilibrating transport we
implemented partition coefficient models and compared the
predictions with intracellular concentration measurements in
Supplementary Text 1. We found overwhelming evidence for
passive diffusion/equilibrating transport as the dominating
mechanism of cellular drug uptake. Moreover, under
passive diffusion and unspecific drug retention, there is a
direct proportionality between plasma concentrations and
concentrations at the site of action. This proportionality implies
that we can model the effect of EFV based on plasma drug
concentrations (derivations in Supplementary Text 1).
3.2. Direct Effects
We modeled the direct effect of efavirenz using the sigmoidal
Emax-equation (Chou, 2006)
ηD(t) =
Dmt
ICm50 + D
m
t
, (5)
TABLE 2 | Pharmacodynamic parameters.
Strain IC50 (± sd) m (± sd) f
wild type 5.4 (± 0.9) 1.69 (±0.08) 1
Y181C 2.8 · IC50(wt) 0.9 ·m(wt) 0.78
K103N 89.1 · IC50(wt) 0.83 ·m(wt) 0.74
G190S 72.1 · IC50(wt) 0.6 ·m(wt) 0.24
The table displays the pharmacodynamic parameters for wild type (Shen et al., 2008)
and different viral mutants (Sampah et al., 2011). The hill coefficient m (unit less) was
assumed to be normal distributed and IC50 values (nmol/L) were assumed to be log-
normal distributed (Jilek et al., 2012). Parameters were corrected for protein binding as
outlined in Supplementary Text 1. Parameter f (unit less) denotes the fitness of the
respective strains. The respective parameter distributions for the mutants (IC50, m) were
computed by assuming an identical coefficient of variation as compared to the wild type.
where Dt is the plasma concentration of the drug at time t, which
is directly proportional to the target-site concentration (previous
section and Supplementary Text 1) and the term IC50 and m
denote the plasma concentration at which the targeted process
is inhibited by 50% and a hill coefficient (Shen et al., 2008),
respectively. Parameters are displayed in Table 2 for wild type,
K103N, Y181C and G190S mutants together with their standard
deviation. Note that the equation above couples the stochastic
viral dynamics (below) to the deterministic pharmacokinetics
(above). The hill coefficient m and 50% inhibitory concentration
IC50 have been measured ex vivo using single-round infection
assays in primary human peripheral blood mononuclear cells,
supplemented with 50% human serum for wild-type HIV and
various resistance mutations (K103N, Y181C and G190S) (Shen
et al., 2008; Sampah et al., 2011). Since the ex vivo assay was
performed with 50% human serum, the measured IC50 has
to be corrected for protein content, since the drugs’ potency
might otherwise be overestimated, particularly for highly protein
bound drugs like EFV. The IC50 correction is demonstrated in
Supplementary Text 1, together with a sensitivity analysis with
regard to uncertainties in measuring the unbound fraction of
EFV in human blood plasma.
3.3. Viral dynamics.
We adopted the viral dynamics model described in von Kleist
et al. (2010) and von Kleist et al. (2011). Long-lived and
latently infected cells are only implicitly considered (outlined
at the end of the section), motivated by the observation that
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transmitted viruses are not macrophage-tropic (Isaacman-Beck
et al., 2009; Ping et al., 2013) and in line with related modeling
approaches (Tan and Wu, 1998; Stafford et al., 2000; Perelson,
2002; Tuckwell et al., 2008; Conway et al., 2013). Although this
model is a simplified representation of the molecular events
happening during virus replication, it allows to accurately and
mechanistically describe the effect of all existing antiretroviral
drug classes on viral replication, as previously reported in (e.g.,
Duwal and von Kleist, 2016), and can be parameterized by in
vitro and clinical data, Table 3. The modeled viral replication
cycle consists of free infectious viruses V , uninfected T-cells
(Tu), early infected T-cells (T1) and productively infected T-cells
(T2). Early infected T-cells (T1) and productively infected
T-cells (T2) denote T-cells prior- and after proviral integration,
respectively, where the latter produces virus progeny. During
the onset of infection the number of viruses is relatively low
and the number of uninfected T-cells Tu is fairly unaffected by
viral dynamics (Perelson et al., 1993; Tan and Wu, 1998; Pearson
et al., 2011). We thus consider Tu = λT/δT to be constant
over the course of simulations. The stochastic dynamics of viral
replication after virus exposure are then defined by six reactions:
a1(Dt) =
(
CLV + CLT(Dt , mut) · Tu
)
· Vt (clearance of free virus; V → ∗) (6)
a2 =
(
δPIC + δT1
)
· T1,t (clearance of early infected cell; T1 → ∗) (7)
a3 = δT2 · T2,t (clearance of late infected cell; T2 → ∗) (8)
a4(Dt) = (1− ηD(t)) · β · f (mut) · Tu · Vt (infection of a susceptible cell; V → T1) (9)
a5 = k · T1,t (proviral integration; T1 → T2) (10)
a6 = NT · T2,t (production of virus; T2 → V+ T2), (11)
with CLT(Dt , mut) =
(
1
ρrev
− (1− ηD(t))
)
· β · f (mut) in
Equation (6), as outlined in von Kleist et al. (2010) where
ρrev = 0.5 denotes the probability to successfully complete
reverse transcription in the absence of inhibitors (Pierson et al.,
2002; Zhou et al., 2005) and f (mut) denotes the fitness of
the mutant. Free viruses can be cleared within T-cells during
unsuccessful infection with rate CLT by destruction of essential
viral components of the reverse transcription-, or pre-integration
complex (Pierson et al., 2002; Zhou et al., 2005) or it may
get cleared by the immune system with a rate constant CLV.
Further, the term β represents the lumped rate of infection of
T-cells, including the processes of virus attachment to the cell,
fusion and reverse transcription, leading to an early infected cell
T1, before proviral integration. The term k denotes the rate by
which early infected T1 cells are transformed into productively
infected T2 cells, involving proviral integration and cellular
reprogramming. The term NT denotes the rate of production
of infectious virus progeny by productively infected T2 cells.
The terms δT1 < δT2 denote the rates of clearance of T1 and
T2 cells, respectively, and δPIC denotes the rate of intracellular
destruction of the pre-integration complex. Parameters for the
viral model are summarized in Table 3. In this article, we
study distinct prophylactic schemes with the non-nucleoside
reverse transcriptase inhibitor efavirenz. Reverse transcriptase
inhibitors act intracellularly on reverse transcription. In our viral
dynamics model this translates into an increase of propensity
function a1 and a proportional decrease in propensity function
a4. Derivations and motivation of this mechanisms of action
from first principles are given in von Kleist et al. (2010)
(Supplementary Methods therein).
3.4. Virus Exposure
Initial viral exposure after sexual intercourse occurs at tissue
sites typically not receptive for establishing and shedding HIV
infection (e.g., mucosal tissues). Hence, the virus needs to pass
several physiological barriers to reach a replication enabling
(target-cell) environment where infection can be established
and from where it can shed systemically (Joseph et al., 2015).
To determine realistic inoculum sizes after sexual exposure
to HIV (initial states for hybrid stochastic simulations), we
previously developed a data-driven statistical model linking
plasma viremia in a transmitter (VL) to the initial viral
population Y0 in a replication-enabling environment (Duwal
et al., 2016) (Supplementary Note 4 therein for details) precisely
capturing average per contact transmission rates for various types
of exposure. In brief, we assume a binomial model
P(Y0 = V|VL = ν) =
(
[νm]
n
)
· rn · (1− r)[ν
m]−n (12)
where [·] is the nearest integer function, m = log10(2.45) is
given by Wilson et al. (2008) and the success probability r was
estimated in a previous work (Duwal et al., 2016) (Supplementary
Note 4 therein), e.g., rhomo = 3.71 · 10
−3 for homosexual- and
rhetero = 3.63 · 10
−4 for heterosexual exposure. The parameter
TABLE 3 | Parameters used for the viral dynamics model.
Parameter Value References Parameter Value References
λT 2·10
9 Wei et al., 1995 k 0.35 Zhou et al., 2005
δT, δT1 0.02 Sedaghat et al., 2009 β 8·10
−12 Sedaghat et al., 2008
δT2 1 Markowitz et al., 2003 NT 670 Sedaghat et al., 2009; von Kleist et al., 2010
δPIC 0.35 Zhou et al., 2005; Koelsch et al., 2008 CLV 2.3 Tan and Wu, 1998; Tuckwell et al., 2008
Excerpt from von Kleist et al. (2010), except for CLV , which assumed that virus clearance is smaller in virus-naive individuals compared to infected individuals, in line with Frank et al.,
2011; Duwal et al., 2012. All parameters refer to the absence of drug treatment ∅. All parameters in units (1/day), except for λ (cells/day) and β (1/(day · virus)).
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VL denotes the viral load in a potential transmitter (assumed to
be log-normal distributed with µ = 4.51, σ = 0.98 (Duwal et al.,
2016)). In this model, the success probability r summarizes both
the extent of local exposure, as well as the probability of passing
all bottlenecking physiological barriers and reaching a replication
enabling target cell compartment. Herein, we used the “exposure
model” to compute drug efficacy estimates after sexual exposure
presented in Figures 3, 4.
3.5. Numerical Simulation
We use the exact numerical simulation scheme proposed
in Duwal et al. (2018). Briefly, the modeled system is split
into stochastic reactions describing viral dynamics and a
set of ordinary differential equations describing individual
EFV pharmacokinetics after drug administration, including
covariates (e.g., CYP2B6 polymorphisms), autoinduction and
the relationship between plasma- and target-site concentrations
outlined above. In our approach EFV pharmacokinetics
affect certain stochastic reaction propensities as outlined in
Equations (6), (9). This hybrid system is then simulated using
the numerically exact EXTRANDE algorithm (Voliotis et al.,
2016) and hybrid trajectories are classified as extinction events
when all viral compartments are cleared. On the other hand,
trajectories were considered infections if (i) either long-lived-
or latently infected cells emerged, or if (ii) the trajectories left
an extinction simplex (ǫ = 0.0001), meaning that it becomes
unlikely (probability≤ ǫ) that the virus will eventually be cleared
(details provided in Duwal et al., 2018).
3.6. Prophylactic Efficacy of a Drug
Regimen
Our goal is to estimate the prophylactic efficacy ϕ of a particular
medication regimen SD. The prophylactic efficacy denotes the
reduction in infection risk per contact, with ϕ =100% indicating
complete protection and ϕ =0% indicating no change in
infection risk.
ϕ(Y0, SD) = 1−
PI(Y0|SD)
PI(Y0|∅)
(prophylactic efficacy), (13)
where PI(Y0|SD) and PI(Y0|∅) denote the virus infection
probabilities for a particular prophylactic scheme SD and in
the absence of prophylactic drugs (∅), respectively, for initial
state Y0 = [V , T1, T2]
T (number of viral particles, early-
and late infected cells in a replication-enabling compartment).
The probabilities PI(Y0|SD) are approximated by the number
of simulations that were classified as infection events divided
by the total number of hybrid stochastic simulation runs for
each particular prophylaxis scheme SD during PrEP, PrEP “on
demand” and PEP simulations. PI(Y0|∅) can be computed using
the analytical formulas derived in Duwal et al. (2019).
Simulation of Pre- and Post-Exposure
Prophylaxis
Codes were written in MATLAB R2018b (MathWorks, Natick,
MA; v. 9.5, including the statistics toolbox). Individual
pharmacokinetic model parameters were drawn from the
distributions defined by the parameter estimates from the
final efavirenz population pharmacokinetic model (Table 2),
generating 1000 virtual patients (Supplementary Table 1). We
then simulated individual pharmacokinetic profiles for the
prophylactic schedule SD under consideration using ode113 in
MATLAB. To simulate different adherence levels, a sequence of
uniformly distributed random numbers with ri ∼ U(0, 1) was
drawn and the ith dose was missed if ri > adherence level.
The number of viruses to be inoculated was drawn from
the virus exposure model, where we first sampled the viral
load in a potential transmitter (log10 VL ∼ N (4.51, 0.98))
and then used the virus load in the transmitter to determine
the number of viruses V0 entering a replication-competent
compartment in the virus-exposed individual using Equation.
(12). Samples with V0 = 0 were rejected (they do not contribute
to the infection risk). For once-daily PrEP simulations with
different adherence levels, a time of virus exposure was randomly
drawn within a 3 month interval starting at day 31 after PrEP
initiation. The corresponding drug concentrations at this time
and the number of transmitted viruses reaching a target cell
compartment were used as the initial states for EXTRANDE
and simulated until stopping criteria were satisfied (either virus
clearance or infection). For “PrEP on demand” simulations, the
time of virus exposure was fixed as indicated in the corresponding
graphics. In the case of PEP, virus was inoculated as stated
above and the stochastic viral dynamics were simulated in the
absence of drugs until the time of PEP initiation (to determine the
initial condition of the system), and henceforth simulated until a
stopping criterium was reached.
In total, for each prophylactic scenario, 10000 simulations
were run and PI(Y0|SD) was computed as the fraction of
simulations that resulted in infection.
4. RESULTS
4.1. Pharmacokinetics
The standard EFV dose used in treatment is 600 mg once daily
taken orally. However, this dose is associated with neurotoxic
effects (Rakhmanina and van den Anker, 2010; Apostolova
et al., 2015), which could be prohibitive when using EFV
as prophylaxis. Notably, neurotoxicity is associated with
EFV plasma concentrations (and CYP2B6 polymorphism)
(Rakhmanina and van den Anker, 2010). Therefore, a
reduced, 400 mg dose has recently been explored, significantly
reducing the risk of neurotoxicity while maintaining sufficient
antiviral effects (ENCORE1 Study Group, 2014; ENCORE1
Study Group et al., 2015).
In Figures 1A,B we depict simulated pharmacokinetics of
once daily oral EFV with 400 and 600 mg. EFV was quickly
absorbed with a median tmax ≈ 5.90h (95% CI: 4.56–7.88) and
has a long median half life t1/2 ≈ 35.57h (CI: 14.28–125.26)
at day 1 and a median half life t1/2 ≈ 20.77h (CI: 8.34–73.15)
after metabolic autoinduction, in agreement with the literature
(Avery et al., 2011, 2013a; Dickinson et al., 2015). Due to its linear
pharmacokinetics, the dose reduction 600→ 400 mg resulted in
a concentration reduction of≈ 2/3 for the 400mg dosing regime.
In Figures 1C,D, we show the long-term pharmacokinetics after
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FIGURE 1 | Efavirenz Pharmacokinetics. Population plasma pharmacokinetics for the first four days after intake of (A) 400- and (B) 600-mg daily oral EFV. Long-term
pharmacokinetics of (C) 400- and (D) 600-mg daily oral EFV due to metabolic autoinduction. Light gray regions encompass 95% of individual PK predictions,
whereas dark gray areas encompass 50% of the predictions (quartiles). The thick red line marks the median pharmacokinetic profiles.
multiple dosing. Two things come to mind: (i) after an initial
plateau phase (4–5 doses), concentrations tend to decrease,
due to metabolic autoinduction, reaching median trough levels
of ≈ 1.35 and ≈ 2.02 mg/L (95% CI: 0.30–6.55 and 0.45–
9.83mg/L) in the 400- and 600mg dosing regime, respectively.
(ii) The variability in the predicted pharmacokinetic profiles
increases after multiple dosing with some individuals achieving
concentrations > 10 (mg/L) (light grey area indicating the 95%
range). This observation is attributable to genetic polymorphisms
affecting some individuals of our virtual patient cohort that
slowly metabolize EFV. Interestingly, there is clinical evidence
that some individuals, particularly slow metabolisers, achieve
concentrations > 10 (mg/L), and that the proportion of these
individuals is much higher for the 600 mg regimen (Dickinson
et al., 2015). In our simulations, 11.3% in the 600 mg group
eventually exceed concentration of 10 mg/L, whereas it is only
2.5% in the 400 mg group. If EFV toxicity is proportional
to exposure, as suggested by Rakhmanina and van den Anker
(2010), this may indicate that dose reduction could significantly
reduce the risk of adverse effects. But is it also protective
against infection?
4.2. Concentration-prophylaxis Profile
We used the analytical solutions presented in Duwal et al.
(2019) to compute concentration-prophylaxis profiles ϕ(Y0, SD)
assuming a single virus particle enters a replication-enabling
compartment (Y0 = [1, 0, 0]
T), see Figure 2A. The reason is
that the virus exposure model (Methods section) predicts that
in most cases only a single virus enters a replication-competent
compartment after (homo-/hetero-)sexual exposure, if a virus
manages at all to pass the various bottlenecking physiological
barriers after sexual exposure. Besides the wild-type virus, we also
show the prophylaxis profile against transmitted drug resistance
with viruses carrying EFV resistance mutations G190S, K103N
and Y181C (Rhee et al., 2003). As a visual guide, the shaded areas
mark the 95% trough (pre-dose) concentration ranges achieved
at plateau and after metabolic autoinduction for once daily 400
mg efavirenz (computed using the POP-PK model).
Figure 2A suggests that once daily EFV (with 400 mg)
provides complete protection against HIV infection after
exposure to wild-type virus and resistant viruses carrying the
Y181C mutation. After exposure to the G190S and K103N
mutants, >>50% protection is provided by once daily 400
mg EFV and >>60% protection by the 600 mg regime. Since
selection of drug resistant variants is a major concern, we
evaluated the relative transmissibility of mutant viruses when
compared with wild-type virus as ϕwt − ϕmut in Figure 2B. The
figure can be interpreted as follows: At low concentrations there
is no reduction in infection if an individual was exposed to
wild-type and/or mutant virus. At an intermediate concentration
range (between 0.001 and 0.1 for Y181C and between 0.001
and 1 mg/L for K103N, G190S, respectively), infections with the
wild type would be prevented, while the prophylaxis cannot, or
only partially reduce the infection risk after exposure to mutant
virus. The maximum corresponds to the maximal difference
in risk reduction, meaning that resistant virus is more likely
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FIGURE 2 | (A) Prophylactic efficacy against different viral genotypes.
Predicted efficacy ranges are depicted as colored shaded areas, with
superimposed mean efficacy estimates as solid lines. Ninety-five percent
confidence intervals of steady-state EFV trough (pre-dose) concentrations
Ctrough,ss for 400 mg EFV after once daily dosing are depicted as light yellow
areas with the vertical black dashed line marking the median trough
concentration. (B) Relative transmissibility ϕwt − ϕmut of mutant viruses.
Colored areas depict the ranges of relative transmissibility and solid lines
indicate the mean relative transmissibility.Yellow shaded areas depict the 95%
CI of EFV trough (pre-dose) concentrations after 400 mg once daily at steady
state. Black dashed vertical lines indicate the corresponding median trough
concentrations. The prophylactic efficacy against a single virus was computed
using the analytical solutions provided in Duwal et al. (2018) (Equation 19–21
therein) for 1000 logarithmically spaced concentrations between 10−4 and 25
mg/L using 1000 sampled values for IC50 and m per viral genotype (Table 2).
For each viral genotype, IC50assay and m were sampled from a log-normal and
normal distribution respectively as stated in the caption of Table 2. IC50assay
were corrected for plasma binding using fu,plasma = 0.2% to obtain
IC50plasma , as outlined in Supplementary Text 1. Changes in drug sensitivity
for the mutants considered the fold changes stated in Table 2. Fitness defects
of the mutants were considered using β(mut) = f (mut) · β(wt).
transmitted than the wild type. At very high EFV concentrations,
the infection risk with both wild type and mutant is reduced.
Importantly, when inspecting (population) median EFV trough
(pre-dose) concentrations after 400mg once daily dosing (dashed
vertical black line in Figure 2B) , we can see that the relative
transmissibility of the Y181C mutant is zero, while the relative
transmissibilities of the G190S and K103N mutants are less
than 20%. The analysis suggests that the typical concentration
ranges achieved after once daily EFV do not, or just slightly,
favor resistance transmission over wild type for the considered
single-substitution mutants. Note that these mutations decrease
EFV susceptibility by ≈ 90 fold, Table 2. However, clinically
derived isolates may contain multiple substitutions and confer
even higher levels of EFV resistance.
Since poor drug adherence may give rise to lower EFV
concentrations and since it is a major factor confounding the
clinical efficacy of Truvada (Haberer et al., 2015), we next set
out to test whether similar issues are to be expected for 400 mg
oral EFV for pre-exposure prophylaxis, or when EFV is used “on
demand” and post-exposure.
4.3. Once-daily PrEP With 400 mg EFV
The predicted prophylactic efficacy of once daily PrEP with
400 mg is shown in Figure 3A as a function of adherence
after exposure to either wild-type virus or after exposure to
drug resistant mutants. As can be seen, if at least 75% of
doses were taken, complete protection against the wild-type
virus and against the Y181C mutant was achieved. Notably,
for these viral genotypes protection was > 95% if 50% of
the pills were taken and ≈ 90% when ≈25% of the pills were
taken. In contrast, after exposure to resistant viruses carrying
the G190S or K103N mutation, protection was >82% when
at least 75% of the once daily 400 mg EFV pills were taken,
gradually dropping to ≈ 50% protection when every fourth pill
was taken.
We next wanted to assess how quickly the prophylactic
protection vanishes, when consecutive EFV doses were missed
(illustratively depicted in Supplementary Figure 1). In order to
do so, we simulated 400 mg EFV-based once daily PrEP with
100% adherence. Subsequently, we computed how long it will
take for the concentrations to drop below the respective 50%,
or 90% protective levels (EC50, EC90). We computed that a
median of 7 (CI: 2–32) consecutive doses need to be missed
in order to provide less than 50% protection against wild-
type virus. Correspondingly, 5 (CI: 1–26) consecutive doses
need to be missed to provide less than 90% protection against
wild-type virus.
4.4. “PrEP on Demand” With 400 mg EFV
Next, we evaluated whether 400 mg EFV “on demand” would
protect against HIV infection. We tested an “on demand” dosing
scheme similar to the one recently tested for Truvada-based PrEP
(Molina et al. , 2015): The first EFV dose was taken within a
time window of 1–23 h prior to virus exposure and followed
by two more doses, 24- and 48- hours after the initial dose.
Our predictions indicate that EFV-based “PrEP on demand”
provides complete protection against wild-type virus and against
the Y181C single mutant, when initiated 1–23 h prior to virus
exposure. Protection against the single mutants G190S and
K103N was still > 81% for 400 mg “PrEP on demand.” This
surprisingly superior prophylactic efficacy of EFV “on demand”
can be attributed to its rapid uptake and slow elimination.
Particularly the latter ensures that virus gets eliminated when
EFV is taken as “PrEP on demand.” The comparatively higher
efficacy of “PrEP on demand,” when compared to once daily
PrEP with low adherence can be explained as follows: In the
case of once-daily PrEP, several consecutive dose intakes may
be missed, which allows the EFV concentrations to fall below
their respective EC50, EC90. If virus exposure occurs during
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FIGURE 3 | Prophylactic efficacy of EFV against the wild-type and resistant virus using different prophylaxis schemes. (A) Predicted prophylactic efficacies for once
daily 400 mg oral EFV PrEP with different levels of adherence. For example in the 25% adherence scheme, each dosing event was randomly missed with 75%
chance. Colored dots mark the median predicted prophylactic efficacy and error bars mark the 95% confidence interval (computed using Greenwood’s formula),
considering variabilities in pharmacokinetic, as well as pharmacodynamic parameters. (B) Predicted prophylactic efficacy of 400 mg oral EFV during “PrEP on
demand” (3 doses) depending on the time of PrEP initiation with respect to viral encounter, respectively. (C) Predicted prophylactic efficacy of post-exposure
prophylaxis (9 doses) with 400 mg oral EFV as a function of the time of PEP initiation after viral challenge. Simulations were conducted using the hybrid EXTRANDE
method outlined in the Methods section. In total, 10,000 stochastic simulations were performed to estimate prophylactic efficacy for each condition (e.g., viral
challenge with K103N during chronic PrEP with 5% adherence is one condition).
FIGURE 4 | Prophylactic efficacy of PEP against wild type virus depending on both the time of PEP initiation and the number of subsequent 400 mg EFV doses taken.
Error bars denote the 95% confidence intervals, computed using Greenwood’s formula. Prophylactic efficacy was estimated for each condition based on 10,000
hybrid EXTRANDE simulations as outlined in the Methods section.
these time windows of low EFV concentrations, infection may
occur (illustrated in Supplementary Figure 1). In contrast, if
all “PrEP on demand” pills are taken, concentrations will be
above the EC90 at the time of exposure, and, due to the
long half life of EFV remain above this value, until the virus
is eliminated (which typically would happen ≤ 1 week post
exposure Konrad et al., 2017).
4.5. Post-Exposure Prophylaxis With 400
mg EFV
Motivated by the promising predictions regarding the use
of EFV in pre-exposure prophylaxis, we also wanted to
investigate whether EFV could prevent infection, if taken as post-
exposure prophylaxis (PEP). In Figure 4, we show the predicted
prophylactic efficacy of 400 mg oral EFV as a function of both the
delay in PEP initiation and the duration of PEP after challenge
with wild-type virus. In Figure 4 it becomes evident that it is
more critical to initiate PEP early after exposure, than to prolong
PEP duration. For example, when PEP is initiated as late as 72
h post virus exposure and the duration of PEP is three days (3
consecutive doses), the prophylactic efficacy was estimated to
be ≈20%. If the duration of PEP was increased to 9 days, the
prophylactic efficacy increases to only ≈40%. However, if PEP
was initiated shortly after virus exposure (e.g., within 2 h), the
prophylactic efficacy increases to 100%, even if the PEP duration
was only 3 days.
As a midpoint, taking the first PEP dose within 24 h post-
exposure resulted in prophylactic efficacies of > 88,> 94,>
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97 and > 98% against the wild type for 3, 5, 7, and 9 dose
intakes, respectively.
Next, we wanted to investigate in more detail the sensitivity
of PEP efficacy towards the timing of PEP initiation in the wild
type and drug resistant mutants. To simplify interpretation, we
assumed a PEP duration of 9 days (9 doses). Predictions are
shown in Figure 3C. PEP provided> 98% protection against the
wild type and the Y181C mutant when started within 12 h after
virus exposure. Protection against viruses containing the G190S
mutation was > 21% using the same parameters, and > 11%
for the K103N mutant. These simulations indicate that EFV may
potently protect against infection with wild type and the weakly
resistant Y181C virus, when initiated within 24 h post expose.
The prophylactic efficacy against transmitted, highly resistant
viruses carrying the G190S or K103N mutation is insufficient for
post-exposure prophylaxis.
5. DISCUSSION
Truvada-based PrEP is being implemented in a number of
countries (AVAC, 2019), however, there are twomajor limitations
to its optimal use: (i) its costs (Keller and Smith, 2011), and (ii) its
sensitivity to poor medication adherence (Haberer et al., 2015).
Current PrEP research focusses on overcoming adherence-
related concerns, either in terms of promoting drug adherence,
or through the development of novel long-acting drugs/drug
formulations for HIV prophylaxis, that only require monthly
drug administration (McGowan et al., 2016; Markowitz et al.,
2017; McMillan et al., 2017). However, little has been done
to investigate cost-efficient Truvada alternatives that may be
affordable in low- and middle-income countries hit hardest by
the epidemic.
A recent computational screen of the prophylactic potential of
treatment-approved compounds for PrEP repurposing suggested
that darunavir, efavirenz, nevirapine, etravirine and rilpivirine
may more potently prevent HIV infection than Truvada at
clinically relevant concentration ranges (Duwal et al., 2019). Of
these candidates we set out to investigate efavirenz in more
detail, since it is both inexpensive and readily available in most
resource-constrained settings.
However, 600 mg EFV has been associated with neurotoxicity
(Rakhmanina and van den Anker, 2010; Apostolova et al., 2015).
Decloedt and Maartens (2013) and Siccardi et al. (2012) have
previously suggested a connection between EFV metabolism
and toxicity, indicating that slow metabolisers, who have higher
plasma concentrations, also have a higher tendency to experience
adverse effects (associations have been made between the
major EFV metabolite and neurotoxicity). The direct association
between plasma concentrations and CNS side effects has also
been reported in Marzolini et al. (2001). Motivated by these
studies, we explicitly considered genetic polymorphisms affecting
EFV metabolism. Moreover, since EFV pharmacokinetics are
linear, dose reductions would naturally lead to decreased EFV
exposure (and consequently toxicity) as investigated in the
ENCORE 1 trial (ENCORE1 Study Group, 2014; ENCORE1
Study Group et al., 2015), which suggested non-inferiority of the
400 mg EFV regimen with regard to treatment. Motivated by
these results, we set out to investigate the prophylactic potential
of 400 mg EFV.
Our simulations strongly suggest that 400 mg efavirenz can
potently prevent infection with drug susceptible HIV, when used
as once daily PrEP, during “PrEP on demand” and even as PEP,
if initiated early enough after exposure (Figures 3, 4). Overall,
these simulations suggest that EFV provides a good efficacy
margin with respect to incomplete adherence and various event-
driven dosing scenarios. Notably, if the association between EFV
toxicity and metabolism is evident, it could also be envisioned
that individuals that experience adverse effects may even further
reduce EFV dosing. For example, using the POP-PK model,
we predicted that the number of patients experiencing plasma
concentrations of > 10 mg/L following a 200mg once daily
dosing regimen is only 0.1%.
However, our simulations also suggested that EFV-based post-
exposure prophylaxis (PEP) may insufficiently protect against
transmitted, highly resistant strains (K103N, G190S), as depicted
in Figure 3C. We should also note that circulating resistant
viruses may have multiple compensatory mutations that increase
fitness and resistance through epistatic effects (Rath et al., 2013).
Thus, their phenotypic attributes may deviate from laboratory
strains with single point mutations that were evaluated in the
present analysis and by Sampah et al. (2011). A recent study
(Zazzi et al., 2018) highlighted high levels of NNRTI resistance
particularly in South Africa, but it is unclear whether the analyzed
NNRTI resistance mutations also confer high level resistance
against EFV. Regarding high level resistance mutations, the
Stanford database currently reports a prevalence πuntreated <<
5% 1 in the untreated population in South Africa, mainly
conferred by K103N. The prevalence of resistance mutations in
treated individuals πtreated is much higher: K103N≈ 30%, Y181C
≈ 20% and G190A/S ≈ 15% 2, but comparable to Truvada
resistance mutations (M184V: 48–60%; K65R: 4–15%) in treated
individuals. Notably, the overall risk of exposure to resistant
strains would be much smaller than these numbers, as it is both
determined by prevalence, as well as the probability of resistance-
associated treatment failure in the donor at the moment of
virus transmission, e.g., mathematically Prob.{exposure to res.} =
Prob.{untreated.}·πuntreated + Prob.{treated.}· Prob.{failing due
to resistance} ·πtreated. The calculations state that resistance
exposure from treated individuals may only originate from those
treated individuals that fail on the treatment at the time of
exposure, due to resistance emergence (if they are successfully
treated at the time of exposure, they are non-contagious
Cohen et al., 2011).
Another important aspect that is quantified in
Supplementary Text 2 is resistance emergence in the
exposed individual prior to PEP initiation. As can be seen in
Supplementary Text 2, the probability of resistance emergence
increases with the delay between virus exposure and PEP
initiation. For example, we calculated that if PEP is initiated
3 days after exposure (72 h), the virus had either gone extinct
1https://hivdb.stanford.edu/page/surveillance-map/
2https://hivdb.stanford.edu/cgi-bin/MutPrevBySubtypeRx.cgi
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or developed resistance with 38% probability. This de novo
resistance may subsequently be selected by EFV, limiting future
treatment options. On the other hand, if PEP is initiated within
12 hours, the probability of resistance emergence in the exposed
individual prior to PEP is <0.01%. Thus, both in terms of
lack of efficacy (Figure 4), as well as in terms of resistance
(Supplementary Text 2), the window of opportunity with
regards to PEP is short. Based on our simulations, PEP should
be initiated as early as possible and is contraindicated if the
suspected virus exposure occurred more than 3 days ago. The
same considerations also apply for Truvada-based prophylaxis.
Our predictions regarding EFV prophylactic efficacy depend
on (i) parameters of EFV potency (IC50) and (ii) the
concentrations of EFV at the target site.
Regarding EFV potency, one limitation of our work is that
we used parameters determined ex vivo (Shen et al., 2008;
Sampah et al., 2011) using primary human peripheral blood
mononuclear cells (PBMCs). These cell mixtures are commonly
used as surrogate markers to determine drug efficacy, since they
contain a large proportion of CD4+ T-cells (the primary HIV
target cell type). Moreover, utilised parameters are generally in
agreement with published values from other sources (Smith et al.,
2001; Parkin et al., 2004; Avery et al., 2013b; Hu and Kuritzkes,
2014; Schauer et al., 2014) (after correction for protein binding;
Supplementary Text 1).
Regarding the relevant target-site concentrations of EFV,
there has been some debate since the total (protein bound and
unbound) EFV concentrations in tissues have been reported
to be highly heterogeneous (Thompson et al., 2015) and some
studies have suggested associations between drug heterogeneity
and incomplete HIV suppression (Fletcher et al., 2014), whereas
others report high concentrations in tissues related to HIV
exposure (Thompson et al., 2015). There are two main
mechanisms that could explain heterogeneous drug distribution,
which we discuss in detail:
a) Active transport (e.g. P-glycoprotein): In this case, the
expression of transporters in particular cell types may cause
concentration differences between distinct tissues. Notably,
active transport would cause a difference in the unbound
concentrations, which are available to exert an antiviral effect.
As a consequence of active eﬄux, lower amounts of EFV
may be available in some relevant target cells, giving rise to
pharmacological sanctuaries relevant to EFV prophylaxis. A
detailed analysis of EFV active transport (Burhenne et al.,
2010) however revealed that it does not affect EFV intracellular
concentrations. Moreover, EFV is a small (molecular mass: 315.6
g/mol) and highly lipophilic (LogP ≈ 4) compound that could
rapidly cross biomembranes by passive diffusion. Thus, even
if EFV was a substrate of cellular transporters, the dominating
(i.e. fastest) mechanism mediating cellular uptake and eﬄux
is probably passive diffusion. Furthermore, passive diffusion
does not imply that the total (protein bound and -unbound)
concentrations on either side of a biomembrane are equal, but
rather implies that the unbound concentrations are equal. I.e.
at each side of a biomembrane, EFV may be (un-)specifically
retained by binding to biomolecules (lipids, proteins, see von
Kleist and Huisinga, 2007 for an overview). However, since
only the unbound concentration is available for drug-target
interaction, EFV concentrations exerting antiviral effects would
be identical in different cell types under passive diffusion.
b) Protein binding: EFV is highly (> 99%) bound to plasma
proteins (Boffito et al., 2003), mainly albumin and α−1-acid
glycoprotein. Naturally, the concentrations of these proteins
are magnitudes lower in tissues, which affects the amount of
protein-bound EFV (and consequently the total concentrations).
Studies that measure unbound drug concentrations lend strong
support to this hypothesis. Avery et al. reported that the
unbound EFV concentrations in plasma and semen (Avery
et al., 2011) and in plasma and cerebrospinal fluid are
nearly identical (Avery et al., 2013a). Importantly, considering
albumin concentrations (calculations in Supplementary Text 1)
in proposed sanctuary sites, we can precisely recover differences
in total EFV concentrations reported, e.g., semen-to-plasma
ratio: 3.4–5 % (Reddy et al., 2002; Avery et al., 2011) and cervical
fluid-to-plasma ratio: 0.4% (Dumond et al., 2007). The fact that
unbound plasma-, cerebrospinal fluid- cervical fluid and semen
concentrations are nearly identical also suggests that EFV can
cross the blood-brain, blood-testis and blood-uterine barrier.
In summary, these combined observations strongly argue
that the distribution of EFV in tissues is governed by passive
diffusion and (un-)specific binding to plasma proteins. In terms
of PK-PDmodeling, this implies that the unbound concentration
in plasma are representative for the unbound concentration
within target cells (CD4+ immune cells/T-cells; derivations
in Supplementary Text 1). When unbound concentrations are
proportionally related to the total concentrations, it also implies
that EFV total plasma concentrations can be used as a marker
of drug efficacy (Marzolini et al., 2001). As a cautionary note
we want to add that there could still be additional unaccounted,
specific barriers lowering EFV unbound concentrations in
physiological sites relevant for establishing the initial infection
upon sexual exposure to HIV-1 (male genital compartment,
female genital compartment and rectum), which warrant further
verification. However, based on the discussions above, we would
strongly disagree with the statement by Dumond et al., that
“agents such as efavirenz that achieve total genital tract exposures
less than 10% of blood plasma are less attractive PrEP/PEP
candidates” (Dumond et al., 2007). This simplistic criterium
of selecting drug candidates ignores the drug’s individual
pharmacology, might only select drugs that are not extensively
protein bound, or select highly protein-bound candidates merely
as a function of genital albumin concentrations. Our simulations
are however in line with a later study from the same group
(Dumond et al., 2012), which find that the concentrations at
the site of virus exposure (in Dumond et al., 2012 the female
genital tract) are proportional to unbound plasma concentrations
during chronic dosing. However, it is unclear after how many
dosing events this equilibrium between plasma and target site
concentrations is achieved. While plasma concentrations rapidly
peak at a tmax of about 5.9 h, there could be a time-delay
in building up concentrations at the site of infection, which
could impair the efficacy of “PrEP on demand” and PEP
(compare Figures 3B,C), in the sense that it becomes more
important to initiate the respective protocols as early as possible.
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Notably, genital tract concentrations measured after the first
dose in Dumond et al. (2007) are in line with our predictions,
arguing for our modeling approach and for the presumed
fast kinetics of cellular uptake by passive diffusion (see also
Supplementary Text 1).
Another limitation of our study is that the parametrization of
the PK model is based on data from HIV-infected individuals,
while prophylaxis is intended for healthy individuals. In fact, it
is unclear whether there are significant differences with respect
to e.g., drug metabolism as a consequence of the infection
status. For example, measured EFV plasma concentrations
(400 mg once daily) in healthy individuals from Burhenne
et al. (2010) are similar to those predicted herein. However,
our model predicts large inter-individual variabilities due to
pharmacogenomics (CYP 450 C2B6 polymorphisms). This hints
toward the fact, that the pharmacokinetic differences between
healthy vs. infected individuals could be small in comparison
to the variability due to CYP polymorphisms. On the other
hand, a study in healthy Ugandan individuals reports EFV
concentrations (Mukonzo et al., 2009) that are considerably
larger than predicted by our model. At the moment it is
unclear whether differences are due to the infection status,
or contributed to differences in ethnicity, weight, or co-
medications: I.e. ethnicity (“black”) has been associated with
lower EFV clearance (Barrett et al., 2002). However, it is
unclear whether concentration differences are due to a higher
proportion of poor metabolisers in Ugandans, as suggested
by Mukonzo et al. (2009), or other factors. It is interesting
to note here that “gender” was a significant co-variate in the
Ugandan study whereas it was not associated with changes
in EFV PK in the ENCORE 1 study (Dickinson et al.,
2015). While the drug’s half life is similar for ENCORE 1
patients (35.57h; CI: 14.28–125.26) and healthy men in the
Ugandan study (Mukonzo et al., 2009) (37.3h in wild type
and 54.7h in slow metabolisers), the drug’s terminal half life
in females in the Ugandan study (Mukonzo et al., 2009) was
twice as large as that for men. For comparison, a meta-
analysis of 16 phase I studies reports a difference of only 10%
(Barrett et al., 2002), warranting further research to clarify
the mechanistic sources of the discrepancy between the results
from the phase I studies (Barrett et al., 2002), the Ugandan
study (Mukonzo et al., 2009) and the data from ENCORE 1
(Dickinson et al., 2015).
Regarding possible co-medications, it is worth mentioning
that efavirenz has a large drug interaction potential. For example,
it has been shown in Fan et al. (2009) that certain herbal
medicines might compete for CYP2B6 metabolisms raising
plasma levels, potentially up to toxic ranges. In any case, toxicity
in the context of EFV-PrEP remains to be elucidated clinically
and it remains to be elucidated if even further dose reductions
would be suitable for PrEP in particular populations. The present
work provides a good starting point to support these decisions,
e.g., based on the concentration-prophylaxis profiles presented
in Figure 2.
Moreover, EFV is an inducer of many CYP
enzymes (Fichtenbaum and Gerber, 2002), possibly
altering the pharmacology of co-medications. Thus,
co-medication with EFV-based PrEP might require
careful monitoring. The Liverpool drug-interaction
database provides an excellent overview over
known effects of EFV on various co-medications
(https://www.hiv-druginteractions.org/).
Overall, this mathematical modelling study argues for the
experimental investigation of EFV as a cost-efficient alternative
PrEP candidate based on its superior prophylactic efficacy and
forgiveness to incomplete adherence and event-driven usage.
However, further analysis emphasising on the safety of EFV in
the context of PrEP/PEP is warranted.
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